Please use this identifier to cite or link to this item: http://gukir.inflibnet.ac.in:8080/jspui/handle/123456789/5309
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHiremath B
dc.contributor.authorMruthyunjayaswamy B.H.M.
dc.date.accessioned2020-06-12T15:06:51Z-
dc.date.available2020-06-12T15:06:51Z-
dc.date.issued2008
dc.identifier.citationActa Pharmaceutica , Vol. 58 , 3 , p. 275 - 285en_US
dc.identifier.uri10.2478/v10007-008-0017-0
dc.identifier.urihttp://gukir.inflibnet.ac.in:8080/jspui/handle/123456789/5309-
dc.description.abstractTwo spectrophotometric methods for the determination of ceftazidime (CFZM) in either pure form or in its pharmaceutical formulations are described. The first method is based on the reaction of 3-methylbenzothiazolin-2-one hydrazone (MBTH) with ceftazidime in the presence of ferric chloride in acidic medium. The resulting blue complex absorbs at ?max 628 nm. The second method describes the reaction between the diazotized drug and N-(1-naphthyl)ethylenediamine dihydrochloride (NEDA) to yield a purple colored product with ?max at 567 nm. The reaction conditions were optimized to obtain maximum color intensity. The absorbance was found to increase linearly with increasing the concentration of CFZM; the systems obeyed the Beer's law in the range 2-10 and 10-50 ?g mL-1 for MBTH and NEDA methods, resp. LOD, LOQ and correlation coefficient values were 0.15, 0.79 and 0.50, 2.61. No interference was observed from common excipients present in pharmaceutical formulations. The proposed methods are simple, sensitive, accurate and suitable for quality control applications.en_US
dc.subjectCeftazidime
dc.subjectDiazotization
dc.subjectPharmaceutical formulation
dc.subjectSpectrophotometry
dc.titleDevelopment and validation of spectrophotometric methods for determination of ceftazidime in pharmaceutical dosage formsen_US
dc.typeArticle
Appears in Collections:1. Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.